Passage Bio (PASG) Competitors

$5.08 -0.04 (-0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$4.88 -0.20 (-3.86%)

As of 05:09 PM Eastern

PASG vs. IZTC, BYSI, IMA, FLNA, and SCLX

Should you buy Passage Bio stock or one of its competitors? MarketBeat compares Passage Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Passage Bio include Invizyne Technologies (IZTC), BeyondSpring (BYSI), ImageneBio (IMA), Cassava Sciences (FLNA), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry.

How does Passage Bio compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Passage Bio has a consensus target price of $13.25, suggesting a potential upside of 160.83%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

Invizyne Technologies' return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Passage Bio	N/A	-150.88%	-59.78%

53.5% of Passage Bio shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Passage Bio had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Passage Bio and 0 mentions for Invizyne Technologies. Passage Bio's average media sentiment score of 1.33 beat Invizyne Technologies' score of 0.00 indicating that Passage Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Passage Bio	Positive

Summary

Passage Bio beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

How does Passage Bio compare to BeyondSpring?

Passage Bio (NASDAQ:PASG) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

BeyondSpring has higher revenue and earnings than Passage Bio. BeyondSpring is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
BeyondSpring	$1.75M	30.31	-$1.01M	-$0.15	N/A

Passage Bio has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

BeyondSpring's return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
BeyondSpring	N/A	N/A	-14.00%

In the previous week, BeyondSpring had 3 more articles in the media than Passage Bio. MarketBeat recorded 5 mentions for BeyondSpring and 2 mentions for Passage Bio. Passage Bio's average media sentiment score of 1.33 beat BeyondSpring's score of 0.98 indicating that Passage Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeyondSpring	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Passage Bio currently has a consensus target price of $13.25, suggesting a potential upside of 160.83%. Given Passage Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Passage Bio is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Passage Bio and BeyondSpring tied by winning 7 of the 14 factors compared between the two stocks.

How does Passage Bio compare to ImageneBio?

Passage Bio (NASDAQ:PASG) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

ImageneBio is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
ImageneBio	N/A	N/A	-$45.35M	-$5.79	N/A

ImageneBio's return on equity of -38.96% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
ImageneBio	N/A	-38.96%	-34.60%

In the previous week, Passage Bio and Passage Bio both had 2 articles in the media. Passage Bio's average media sentiment score of 1.33 beat ImageneBio's score of 0.36 indicating that Passage Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Passage Bio presently has a consensus price target of $13.25, suggesting a potential upside of 160.83%. ImageneBio has a consensus price target of $26.50, suggesting a potential upside of 404.76%. Given ImageneBio's higher possible upside, analysts plainly believe ImageneBio is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Passage Bio has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by company insiders. Comparatively, 5.9% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ImageneBio beats Passage Bio on 8 of the 13 factors compared between the two stocks.

How does Passage Bio compare to Cassava Sciences?

Passage Bio (NASDAQ:PASG) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Passage Bio had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Passage Bio and 0 mentions for Cassava Sciences. Passage Bio's average media sentiment score of 1.33 beat Cassava Sciences' score of 0.00 indicating that Passage Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Passage Bio	Positive
Cassava Sciences	Neutral

Cassava Sciences' return on equity of -53.90% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Cassava Sciences	N/A	-53.90%	-34.20%

Cassava Sciences is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Passage Bio presently has a consensus price target of $13.25, suggesting a potential upside of 160.83%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 4.9% of Passage Bio shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Passage Bio has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, suggesting that its stock price is 175% less volatile than the broader market.

Summary

Passage Bio beats Cassava Sciences on 10 of the 13 factors compared between the two stocks.

How does Passage Bio compare to Scilex?

Passage Bio (NASDAQ:PASG) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by company insiders. Comparatively, 4.1% of Scilex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Passage Bio has higher earnings, but lower revenue than Scilex. Passage Bio is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Scilex	$30.25M	1.68	-$358.73M	-$36.45	N/A

Passage Bio presently has a consensus price target of $13.25, indicating a potential upside of 160.83%. Given Passage Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Passage Bio is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Passage Bio had 1 more articles in the media than Scilex. MarketBeat recorded 2 mentions for Passage Bio and 1 mentions for Scilex. Passage Bio's average media sentiment score of 1.33 beat Scilex's score of 0.00 indicating that Passage Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Passage Bio has a net margin of 0.00% compared to Scilex's net margin of -1,185.78%. Scilex's return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Scilex	-1,185.78%	N/A	-178.57%

Passage Bio has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Scilex has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Summary

Passage Bio beats Scilex on 10 of the 15 factors compared between the two stocks.

Get Passage Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PASG vs. The Competition

Export

Metric	Passage Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.31M	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-0.43	18.70	20.58	25.11
Price / Sales	N/A	278.20	577.42	91.32
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	0.86	6.57	9.68	6.60
Net Income	-$45.52M	$24.30M	$3.55B	$335.71M
7 Day Performance	0.99%	-3.56%	-2.07%	-2.03%
1 Month Performance	-56.47%	-7.86%	-3.90%	-1.90%
1 Year Performance	-14.77%	51.80%	29.39%	27.36%

Passage Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PASG Passage Bio	3.5351 of 5 stars	$5.08 -0.8%	$13.25 +160.8%	-15.2%	$16.31M	N/A	N/A	130	News Coverage Positive News Earnings Report Short Interest Increase
IZTC Invizyne Technologies	N/A	$9.62 -3.8%	N/A	-35.1%	$60.14M	N/A	N/A	29	Gap Down
BYSI BeyondSpring	0.3201 of 5 stars	$1.45 -4.6%	N/A	-16.0%	$59.62M	$1.75M	N/A	80	News Coverage Earnings Report Gap Up
IMA ImageneBio	2.7433 of 5 stars	$5.59 -0.4%	$26.50 +374.1%	-57.6%	$59.53M	$800K	N/A	70	Analyst Downgrade
FLNA Cassava Sciences	0.1167 of 5 stars	$1.23 -4.3%	N/A	-43.1%	$59.18M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PASG) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Passage Bio (PASG) Competitors

PASG vs. IZTC, BYSI, IMA, FLNA, and SCLX

How does Passage Bio compare to Invizyne Technologies?

Summary

How does Passage Bio compare to BeyondSpring?

Summary

How does Passage Bio compare to ImageneBio?

Summary

How does Passage Bio compare to Cassava Sciences?

Summary

How does Passage Bio compare to Scilex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Passage Bio (PASG) Competitors

PASG vs. IZTC, BYSI, IMA, FLNA, and SCLX

How does Passage Bio compare to Invizyne Technologies?

Do analysts rate IZTC or PASG?

Which has preferable valuation & earnings, IZTC or PASG?

Is IZTC or PASG more profitable?

Do institutionals & insiders have more ownership in IZTC or PASG?

Does the media prefer IZTC or PASG?

Summary

How does Passage Bio compare to BeyondSpring?

Which has preferable earnings & valuation, PASG or BYSI?

Which has more volatility and risk, PASG or BYSI?

Is PASG or BYSI more profitable?

Does the media refer more to PASG or BYSI?

Do analysts rate PASG or BYSI?

Do insiders and institutionals hold more shares of PASG or BYSI?

Summary

How does Passage Bio compare to ImageneBio?

Which has stronger valuation & earnings, PASG or IMA?

Is PASG or IMA more profitable?

Does the media refer more to PASG or IMA?

Do analysts rate PASG or IMA?

Which has more risk & volatility, PASG or IMA?

Do institutionals & insiders hold more shares of PASG or IMA?

Summary

How does Passage Bio compare to Cassava Sciences?

Does the media refer more to PASG or FLNA?

Is PASG or FLNA more profitable?

Which has higher earnings & valuation, PASG or FLNA?

Do analysts recommend PASG or FLNA?

Do insiders & institutionals have more ownership in PASG or FLNA?

Which has more risk & volatility, PASG or FLNA?

Summary

How does Passage Bio compare to Scilex?

Do insiders & institutionals believe in PASG or SCLX?

Which has better earnings & valuation, PASG or SCLX?

Do analysts recommend PASG or SCLX?

Does the media refer more to PASG or SCLX?

Is PASG or SCLX more profitable?

Which has more risk & volatility, PASG or SCLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools